Biofrontera publishes report on the third quarter of 2014 - Seite 4
The management board of Biofrontera AG will outline the main developments in the period under review in a telephone conference.
The telephone conference for shareholders and potential investors begins in German at 9:00 AM, and in English at 10:30 AM.
Telephone conference in German:
Access number: +49-(0)69 271340800
Confirmation number: 73218216#
Telephone conference in English:
Access number: +49-(0)69 271340801
Access UK: +44 20 33645807
Confirmation number: 51595435#
Please dial in 5 minutes before the start of the telephone conference to enable the conference to start on time.
For inquiries, please contact:
Biofrontera AG Prof. Hermann Lübbert, Chairman of the Management Board Thomas Schaffer, Chief Financial Officer |
+49 (0) 214 87 63 2 0 press@biofrontera.com www.biofrontera.com |
||
Brainwell Asset Solutions Jürgen Benker |
+49 (0) 152 08931514 | ||
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.
Lesen Sie auch
The company also markets the Belixos® dermatological range of cosmetics. Belixos® contains a combination of active substances extracted from plants, relieves itching and redness and is used for the regenerative treatment of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® is available as a cream and scalp tonic.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;